anonymous
Guest
anonymous
Guest
Acthar is way cheaper than Humira.
Payors coming online with more indications.
Nice.
Payors coming online with more indications.
Nice.
$20,000 ago. Pre Obamacare and healthcare debate. Are dumb enough to not realize the FDA is essentially a political organization? If you don’t think that is true look at how political the FBI and IRS have become in the past decade. Don’t think for a second the FDA consulting in the early 2000’s means a damn thing now. Congress, the FDA and the federal government don’t care a wit about that and if beating up Acthar and MNK helps them score political points they are more than willing to beat us until we can be beat no moreLOL! FDA was the one who consulted on the pricing. How stupid are you?
LOL! FDA was the one who consulted on the pricing. How stupid are you?
You can keep spouting this same shit but anyone who saw Nate’s slides this week knows that we are down DRAMATICALLY from both 60 minutes and then Even a bigger leg down post CNN. Fall in love with the Q2 results of you want but Q3 and Q4 are going to be disastrous.Acthar rev hitting $300M for Q2.
Acthar rev hitting $300M for Q2.
Acthar rev hitting $300M for Q2.
Acthar rev hitting $300M for Q2.
Liar.
Acthar revenue $297M.
Actually 293.2 no need to exaggerate. If you understood the business you wouldn’t be that impressed. Wait for Q3 and Q4 you won’t be celebrating. They still won’t get 1 biWhat a great quarter. Acthar is back and better than ever! I can see this going to 2 billion next year easy.
wont get to 1 billion this year and will do even less in 2019. It’s a downward trend jackass not upward. 2016 WAS the PEAK at $1.267 they will never hit that again. If stock hits $35 it’s a great time to short back to $20Actually 293.2 no need to exaggerate. If you understood the business you wouldn’t be that impressed. Wait for Q3 and Q4 you won’t be celebrating. They still won’t get 1 bi